With Dupixent, Sanofi is aiming for a peak turnover of over 13 billion euros

Sanofi annual results
FILE PHOTO: Sanofi logo at the company’s headquarters during the annual press conference in Paris, France, February 4, 2022. REUTERS/Benoit Tessier

March 29, 2022

PARIS (Reuters) – French healthcare group Sanofi, which has been lagging behind rivals in the COVID-19 vaccine race, on Tuesday raised its peak sales target for eczema treatment product Dupixent to more than 13 billion euros ($14.3 billion).

“This new target does not include the potential for an additional increase in the chronic obstructive pulmonary disease (COPD) revenue target, with key metrics expected in 2023,” Sanofi said in a statement.

Earlier this month, analysts at investment bank JP Morgan said they expected Sanofi to raise its peak sales forecast for Dupixent to about $15 billion.

Sanofi is working with UK partner GlaxoSmithKline to develop a COVID-19 vaccine.

Sanofi also announced Tuesday a partnership with US company IGM Biosciences in the field of oncology, immunology and inflammation treatments.

($1=0.9096 euros)

(Reporting by Sudip Kar-Gupta; Editing by Clarence Fernandez and Jacqueline Wong) With Dupixent, Sanofi is aiming for a peak turnover of over 13 billion euros


USTimeToday is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Back to top button